Tus kws kho mob
P66-17 Clarification of Mid-Level Definitions
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 06, 2017
Tshawb Nrhiav
Nthuav pom cov txiaj ntsig tshwm sim 3261 - 3270 ntawm 3669
Tus kws kho mob
P17-17 Addition of Drug Kisqali to the Self-Administered Oncology Prior Authorization with Quantity Limit Program
Hnub Tim pib siv tau lub khoos kas: Lub Plaub Hlis Ntuj Tim 28, 2017
Tus kws kho mob
P22-17 Identified Claims Processing Issues Grid
Hnub Tim pib siv tau lub khoos kas: Lub Tsib Hlis Ntuj Tim 10, 2017
Tus kws kho mob
P35-16 Requirement to Submit National Drug Codes and Related Information
Hnub Tim pib siv tau lub khoos kas: Lub Xya Hli Ntuj Tim 27, 2016
Tus kws kho mob
P27-16 Changes to Prior Authorization Requirements for Select Services for Commercial Products
Hnub Tim pib siv tau ntawm lub khoos kas: Rau Hlis Ntuj Tim 08, 2016
Tus kws kho mob
P4-17 Addition of Drug to the Self-Administered Oncology Prior Authorization with Quantity Limit Program
Hnub Tim pib siv tau lub khoos kas: Lub Ib Hlis Ntuj 30, 2017
Tus kws kho mob
P34-16 New Drug-Related Prior Authorization Criteria for Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) Channel Blocker Prior Authorization with Quantity Limit Program
Hnub Tim pib siv tau lub khoos kas: Lub Xya Hli Ntuj Tim 27, 2016
Tus kws kho mob
P47-16 New Drug-Related Prior Authorization Requirements for Botulinum Toxin, Remicade, Rituxan and Biologic Immunomodulators
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Hlis Ntuj Tim 10, 2016
Tus kws kho mob
P50-16 Addition of a Drug (Xiidra) to the Ophthalmic Immunomodulators Prior Authorization with Quantity Limit Program
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Hlis Ntuj Tim 28, 2016
Tus kws kho mob
P53-16 New Notification Requirement for Outpatient Dialysis Services for Commercial Products and Subscribers in Government Programs
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 09, 2016